LONDON--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, and NHS England today announced the availability of the easy ...

DexCom (NasdaqGS:DXCM) is seeing higher adoption of its continuous glucose monitoring systems among patients using GLP-1 drugs, as physicians pair both therapies for diabetes care. The company is ...

Dexcom has been abuzz this year amid the European approval—and submission for FDA approval in the U.S.—for its next-generation G7 continuous glucose monitoring system, which promises more accurate ...

LONDON--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...

On the heels of the latest NICE guidelines, Dexcom ONE is in review by NHS England for addition to the Drug Tariff Dexcom ONE, a wearable sensor and transmitter, puts people firmly in control of their ...

This year’s Diabetes Awareness Week (13-19 June) is celebrating the triumphs and challenges for all people with diabetes. To celebrate the week, as well as the updated NICE (National Institute of ...

DexCom Inc. DXCM recently announced the direct connectivity of the Dexcom G7 Continuous Glucose Monitoring (CGM) system with the Apple Watch. This added feature is now available to users in the United ...

In February 2026, DexCom reported fourth-quarter 2025 sales of US$1,259.6 million and full-year 2025 sales of US$4,662 million, with net income rising to US$267.3 million for the quarter and US$836.3 ...

Wider use of the Dexcom G6 real-time continuous glucose monitoring (RT-CGM) system in the United Kingdom would be cost-effective in the long term, new research suggests. The analysis was published in ...

Truist Securities initiated coverage on DexCom (NASDAQ:DXCM) with a Buy rating and a $102.00 price target Monday, citing the company’s position in the continuous glucose monitoring market. According ...